Anti-VEGF therapy may revolutionize ROP treatment
A single intravitreal injection of an anti-VEGF agent in babies with retinopathy of prematurity
induces regression of pathological neovascularization and also promotes resumption of
physiological vascularization of the retina, Tim U Krohne MD of the University of Bonn Eye
Clinic told the World Society of Paediatric Ophthalmology & Strabismus. As such, it could
eliminate the need to ablate avascular retina tissue and has the potential to revolutionize ROP
treatment.
However, several issues must be addressed before anti-VEGF is adopted, Dr Krohne said. These
include establishing the smallest effective dose and assessing safety with particular attention to
systemic side effects. Injection sight is also an issue since premature infant eyes are very small.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.